IDF2022-0559 Efficacy and safety of empagliflozin as an add on to metformin and DPP4 inhibitor in T2DM patients, fasting during Ramadan. (March 2023) - Pathan, M.F.; Akter, N.; Selim, S.; Saifuddin, M.; Qureshi, N.K.; Hasan, A.B.M.K.; Hannan, M.A.; Ahmed, M.A.U.; Mustari, M.; Chakraborty, A.K.